ZURA BIO LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.495 USD | -1.43% |
|
-10.24% | -2.36% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 203.6 | 284.2 | - | - |
| Enterprise Value (EV) 1 | 203.6 | 284.2 | 284.2 | 284.2 |
| P/E ratio | -2.23 x | -8.81 x | -5.81 x | -4.56 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -6.93 x | -5.92 x | -3.55 x |
| FCF Yield | - | -14.4% | -16.9% | -28.1% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 43,594 | 62,326 | - | - |
| Reference price 2 | 4.670 | 4.560 | 4.560 | 4.560 |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -62.64 | -39.62 | -61.37 | -86.41 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -60.56 | -36.69 | -58.04 | -83.03 |
| Net income 1 | -60.36 | -36.69 | -58.04 | -83.03 |
| Net margin | - | - | - | - |
| EPS 2 | -2.090 | -0.5175 | -0.7850 | -1.000 |
| Free Cash Flow 1 | - | -41 | -48 | -80 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -33.9 | -10.19 | -10.83 | -8.379 | -8.953 | -10.1 | -12.34 | -12.96 | -14.19 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -34.02 | -8.27 | -8.473 | -7.747 | -8.337 | -9.178 | -11.44 | -11.85 | -13.04 |
| Net income 1 | -9.592 | -44.9 | -8.27 | -8.473 | -7.747 | -8.337 | -9.178 | -11.44 | -11.85 | -13.04 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -1.310 | -0.1800 | - | -0.0200 | -0.1400 | -0.1450 | -0.1675 | -0.1667 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/05/23 | 14/08/23 | 13/11/23 | 28/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -41 | -48 | -80 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2.54 | 2.55 | 2.55 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.56
USD
Average target price
19.75
USD
Spread / Average Target
+333.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.36% | 284M | |
| +18.18% | 125B | |
| +14.34% | 109B | |
| -2.13% | 24.74B | |
| +2.71% | 22.67B | |
| -9.95% | 18.14B | |
| -41.48% | 16.67B | |
| -12.44% | 16.64B | |
| +0.36% | 13.45B | |
| +23.45% | 11.32B |
- Stock Market
- Equities
- ZURA Stock
- Financials Zura Bio Limited
